ArriVent BioPharma Quarterly Income Statement
NASDAQ: AVBPHealth CareBiotechnology: Pharmaceutical PreparationsUSD
16.73+0.02 (+0.12%)
At close: Oct 9, 4:00 PM ET · Delayed 15 min
ArriVent BioPharma revenue and earnings
ArriVent BioPharma reported a net loss of $49.9 million, compared with a loss of $31.4 million a year earlier. Diluted earnings per share came in at -$1.05.
Summary generated from market data by MetaCap's automated system. Methodology
ArriVent BioPharma income statement (quarterly)
| Quarter (USD) | Q2 20262026-06-30 | Q1 20262026-03-31 | Q4 20252025-12-31 | Q3 20252025-09-30 | Q2 20252025-06-30 | Q1 20252025-03-31 | Q4 20242024-12-31 | Q3 20242024-09-30 | Q2 20242024-06-30 | Q1 20242024-03-31 | Q4 20232023-12-31 | Q3 20232023-09-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Expenses | 52.69M | 46.11M | 38.82M | 38.32M | 33.62M | 66.77M | 23.70M | 24.23M | 25.70M | 20.67M | 23.12M | 16.72M |
| Research & Development | 42.34M | 37.62M | 32.17M | 32.17M | 27.72M | 61.29M | 20.16M | 20.09M | 21.78M | 16.98M | 20.01M | 14.28M |
| Operating Income | -52.69M | -46.11M | -38.82M | -38.32M | -33.62M | -66.77M | -23.70M | -24.23M | -25.70M | -20.67M | -23.12M | -16.72M |
| Net Income | -49.89M | -43.32M | -35.54M | -34.98M | -31.40M | -64.39M | -20.63M | -20.56M | -21.87M | -17.42M | -21.19M | -14.40M |
| Net Income growth (YoY) | — | — | — | — | — | — | — | — | — | — | — | — |
| EPS (Basic) | -1.05 | -0.96 | -0.69 | -0.83 | -0.90 | -1.90 | -0.60 | -0.61 | -0.65 | -0.70 | -6.62 | -5.52 |
| EPS (Diluted) | -1.05 | -0.96 | -0.69 | -0.83 | -0.90 | -1.90 | -0.60 | -0.61 | -0.65 | -0.70 | -6.62 | -5.52 |
| Shares Outstanding (Basic) | 47.61M | 45.07M | — | 41.91M | 35.01M | 33.90M | — | 33.58M | 33.50M | 25.05M | — | 2.61M |
| Shares Outstanding (Diluted) | 47.61M | 45.07M | — | 41.91M | 35.01M | 33.90M | — | 33.58M | 33.50M | 25.05M | — | 2.61M |
| EBITDA | -53.21M | -46.67M | — | — | — | — | — | — | — | — | — | — |
This table shows 12 quarterly periods of ArriVent BioPharma's income statement, from Q2 2026 back to Q3 2023, across 9 line items including operating expenses, research & development, operating income. Values in USD; B = billions, M = millions. Fiscal periods follow AVBP's reporting calendar. What is a income statement?